These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38252503)

  • 1. Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study.
    Matsui T; Yoshida T; Nishino T; Yoshizawa S; Sawada T; Tohma S
    Mod Rheumatol; 2024 Aug; 34(5):881-891. PubMed ID: 38252503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.
    Innala L; Berglin E; Möller B; Ljung L; Smedby T; Södergren A; Magnusson S; Rantapää-Dahlqvist S; Wållberg-Jonsson S
    Arthritis Res Ther; 2014 Apr; 16(2):R94. PubMed ID: 24731866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
    Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Li X; Cesta A; Movahedi M; Bombardier C
    Arthritis Res Ther; 2022 Nov; 24(1):255. PubMed ID: 36401335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).
    Asai S; Suzuki M; Hara R; Hirano Y; Nagamine S; Kaneko T; Suto T; Okano T; Yoshioka Y; Hirao M; Wakabayashi H; Fujibayashi T; Watanabe T; Takakubo Y; Ishikawa H; Nasu Y; Takemoto T; Kato T; Torikai E; Koyama K; Takagi H; Fujiwara T; Sobue Y; Ohashi Y; Nishiume T; Terabe K; Kojima M; Kojima T; Imagama S
    Mod Rheumatol; 2024 Aug; 34(5):892-899. PubMed ID: 38491996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late onset rheumatoid arthritis an observational study.
    Rexhepi S; Rexhepi M; Sahatçiu-Meka V; Rexhepi B; Bahtiri E; Mahmutaj V
    Reumatizam; 2016; 63(1):1-5. PubMed ID: 29616535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account.
    Huscher D; Sengler C; Gromnica-Ihle E; Bischoff S; Eidner T; Ochs W; Richter J; Zink A
    Clin Exp Rheumatol; 2013; 31(2):256-62. PubMed ID: 23305590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disease activity and therapeutic strategy of patients with late-onset rheumatoid arthritis].
    Yang M; Liang Y; Cen XM; Xie QB; Yin G
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 46(2):289-92. PubMed ID: 25924448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan.
    Kaneko Y; Sakurai M; Snijder R; Kokubo S; Kato D
    Mod Rheumatol; 2023 Apr; 33(3):448-459. PubMed ID: 35640001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE EMERGENCE OF RHEUMATOID ARTHRITIS AT THE AGE OF OVER 60 - A COMPARISON OF CLINICAL MANIFESTATIONS AND ACCESS TO TREATMENT PATTERN COMPARED TO YOUNGER PATIENTS].
    Balbir-Gurman A; Arabi-Zuhabi A; Braun-Moscovici Y
    Harefuah; 2019 Sep; 158(9):563-567. PubMed ID: 31507104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
    Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus statement on the management of late-onset rheumatoid arthritis.
    Kojima M; Sugihara T; Kawahito Y; Kojima T; Kaneko Y; Ishikawa H; Abe A; Matsui K; Hirata S; Kishimoto M; Tanaka E; Morinobu A; Hashimoto M; Matsushita I; Hidaka T; Matsui T; Nishida K; Asai S; Ito H; Harada R; Harigai M
    Mod Rheumatol; 2024 Oct; 34(6):1095-1102. PubMed ID: 38511322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study.
    Miyakawa N; Tsuritani K; Teixeira BC; Fujio K
    Mod Rheumatol; 2024 Aug; 34(5):900-909. PubMed ID: 38450776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatments of rheumatoid arthritis: from the 'NinJa' registry.
    Saeki Y; Matsui T; Saisho K; Tohma S
    Expert Rev Clin Immunol; 2012 Jul; 8(5):455-65. PubMed ID: 22882220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.